At what enterprise value was WINNCARE acquired in 2026?

You can find the full valuation details of WINNCARE on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of WINNCARE when it was acquired by SIPAREX?

The exact EV/EBITDA multiple for WINNCARE is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was WINNCARE acquired by SIPAREX?

WINNCARE was acquired by SIPAREX in 2026.

What was the revenue of WINNCARE at the time of the deal?

The revenue of WINNCARE at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of WINNCARE during the acquisition?

WINNCARE's EBITDA is estimated to be in the range of 5M - 25M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the WINNCARE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the WINNCARE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.siparex.com/wp-content/uploads/2026/03/CP-Siparex-ETI-Winncare-23-03-26.pdf

← DATABASE

Home Database Healthcare & PharmaWINNCARE

03/2026

WINNCARE acquired by SIPAREX

FRANCE Life Sciences / Medical Devices REV 100M - 200M EUR

Context

Siparex has reaffirmed its commitment to Winncare by leading a quaternary LBO to retain control of the medical device manufacturer. This transaction allows Siparex, which originally acquired the company in 2021 via its ETI 5 fund, to extend the maturity of its investment while slightly increasing its ownership stake alongside the management team led by President Laurent Faugères. The deal marks a significant restructuring of the minority capital: IDI, which had been an investor since 2014, and Capza have both exited their positions. They are replaced by Kartesia, which entered the capital through a combination of equity and mezzanine debt after a competitive process managed by the investment bank Amala. The strategic rationale for this "prolongation" is driven by Winncare,s strong performance, having doubled its revenue from €75M to €150M in the last five years through a successful buy-and-build strategy involving four acquisitions. The new capital structure is designed to provide the group with the financial flexibility to launch a new phase of consolidation in Europe and North America. The deal is supported by a new senior debt package provided by Crédit Agricole CIB, while historical minority partners BNP Paribas Développement and Crédit Agricole have maintained their stakes. This operation highlights the "essential" nature of Winncare,s products in a market characterized by high demand for elderly care solutions and professionalized home-care equipment.

In the past, the company underwent an LBO led by Siparex in 2021, and continued an active consolidation strategy by notably acquiring Pharmaouest Industries (2021).

WINNCARE, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Winncare is a leading European manufacturer of medical devices specifically designed for the care of individuals with loss of autonomy. The company,s product portfolio includes high-tech anti-bedsore mattresses, medicalized beds, and patient-handling solutions aimed at improving the quality of life for the elderly and those in rehabilitation. Operating with an industrial business model, Winncare supplies its essential medical equipment to nursing homes, hospitals, and home-care providers globally. Its value proposition is built on technical innovation and the reliability of its "first-necessity" products, which address the growing healthcare demands of an aging global population. The group,s strategy centers on being a consolidation platform in the specialized medical furniture market, leveraging a robust R&D pipeline to maintain regulatory compliance and clinical efficacy. By integrating digital solutions into its hardware, Winncare ensures better patient monitoring and caregiver efficiency. The company maintains a strong international presence, focusing on expanding its manufacturing and distribution footprint across Europe and North America through both organic innovation and strategic industrial acquisitions.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2025

2024

Other operations with WINNCARE

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
12/2021	WINNCARE	PHARMAOUEST INDUSTRIES	FRANCE	Life Sciences	This transaction marks the first major structural acquisition for Winncare following the entry of Siparex ETI as its majority shareholder earlier in 2021. By acquiring 100% of Pharmaouest Industries, Winncare has significantly strengthened its industrial capabilities and product portfolio in the high-stakes segment of pressure ulcer prevention
02/2021	SIPAREX	WINNCARE	FRANCE	Life Sciences	Siparex ETI has entered into exclusive negotiations to acquire a majority stake in Winncare, marking the first investment of its Siparex ETI 5 fund. This transaction follows a successful period of ownership by IDI, which originally took control of the group in 2014 and supported a doubling of the company,s size through international expansion

REFERENCES

Revenue range: 100M - 200M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of WINNCARE by SIPAREX are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: winncare

Acquirer: siparex